Interactions of amphetamine analogs with human liver CYP2D6

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

B. Schmid, J Bircher, R Preisig et al. · Clinical Pharmacology & Therapeutics · 1985 · 386 citations

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

K. Br�sen, L. F. Gram · European Journal of Clinical Pharmacology · 1989 · 285 citations

Mendelian Disorder, Sparteine/debrisoquine Oxidation Polymorphism, Genetics +4

Inhibition by fluoxetine of cytochrome P450 2D6 activity

S V Otton, Dafang Wu, Russell T. Joffe et al. · Clinical Pharmacology & Therapeutics · 1993 · 260 citations

The metabolic fate of amphetamine in man and other species

L. G. Dring, Robert L. Smith, R. T. Williams · Biochemical Journal · 1970 · 248 citations · Full text

Psychopharmacology, Experimental Pharmacology, Social Sciences +19

The demethylenation of methylenedioxymethamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6)

Geoffrey T. Tucker, M. S. Lennard, S. W. Ellis et al. · Biochemical Pharmacology · 1994 · 236 citations

Medicinal Chemistry, Psychoactive Drug, Biochemistry +9